Pages that link to "Q28266298"
Jump to navigation
Jump to search
The following pages link to Population frequencies of inherited neuromuscular diseases—A world survey (Q28266298):
Displaying 50 items.
- SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy (Q21560963) (← links)
- SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy (Q21562176) (← links)
- Corticosteroids for the treatment of Duchenne muscular dystrophy (Q24185788) (← links)
- Respiratory muscle training in children and adults with neuromuscular disease (Q24188193) (← links)
- Interventions to prevent steroid-induced osteoporosis and osteoporotic fractures in Duchenne muscular dystrophy (Q24198280) (← links)
- Interventions for increasing ankle range of motion in patients with neuromuscular disease (Q24240063) (← links)
- Aminoglycosides and other nonsense suppression therapies for the treatment of dystrophinopathy (Q24240721) (← links)
- Glucocorticoid corticosteroids for Duchenne muscular dystrophy (Q24242199) (← links)
- Drug treatment for myotonia (Q24244905) (← links)
- Glucocorticoid corticosteroids for Duchenne muscular dystrophy (Q24247197) (← links)
- Drug treatment for myotonia (Q24247351) (← links)
- The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy (Q24308680) (← links)
- β–sarcoglycan: characterization and role in limb–girdle muscular dystrophy linked to 4q12 (Q24312878) (← links)
- Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A (Q24314667) (← links)
- A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene (Q24538715) (← links)
- The epidemiology of Leber hereditary optic neuropathy in the North East of England (Q24611047) (← links)
- Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy (Q24621454) (← links)
- The Dietary Supplement Protandim® Decreases Plasma Osteopontin and Improves Markers of Oxidative Stress in Muscular DystrophyMdxMice (Q24628875) (← links)
- Non-operative treatment for perforated gastro-duodenal peptic ulcer in Duchenne muscular dystrophy: a case report (Q24791640) (← links)
- Detection of mutations in the dystrophin gene via automated DHPLC screening and direct sequencing (Q24794339) (← links)
- Current and emerging treatment strategies for Duchenne muscular dystrophy (Q26741535) (← links)
- Myotonic disorders: A review article (Q26747746) (← links)
- Metabogenic and Nutriceutical Approaches to Address Energy Dysregulation and Skeletal Muscle Wasting in Duchenne Muscular Dystrophy (Q26772002) (← links)
- Prevalence of neurogenetic disorders in the North of England (Q26784050) (← links)
- Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options (Q26785627) (← links)
- Facioscapulohumeral distrophy and physiotherapy: a literary review (Q26796651) (← links)
- Stem cells for skeletal muscle regeneration: therapeutic potential and roadblocks (Q26828390) (← links)
- Neuropathic pain in hereditary peripheral neuropathy (Q26860768) (← links)
- Bone health and associated metabolic complications in neuromuscular diseases (Q27025688) (← links)
- Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy (Q27302822) (← links)
- Spatio-Temporal Differences in Dystrophin Dynamics at mRNA and Protein Levels Revealed by a Novel FlipTrap Line (Q27304985) (← links)
- Differential Gene Expression Profiling of Dystrophic Dog Muscle after MuStem Cell Transplantation (Q27309883) (← links)
- Quality improvement in neurology: muscular dystrophy quality measures (Q27348818) (← links)
- Modifier genes and their effect on Duchenne muscular dystrophy (Q28083441) (← links)
- Genetic evidence in the mouse solidifies the calcium hypothesis of myofiber death in muscular dystrophy (Q28085320) (← links)
- Abnormal fatty acid metabolism in childhood spinal muscular atrophy (Q28138438) (← links)
- Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway. (Q28243993) (← links)
- Clinical approach to the diagnostic evaluation of hereditary and acquired neuromuscular diseases (Q28273990) (← links)
- Phase II open label study of valproic acid in spinal muscular atrophy (Q28475498) (← links)
- Epigenetic changes as a common trigger of muscle weakness in congenital myopathies (Q29977760) (← links)
- Musculoskeletal simulation can help explain selective muscle degeneration in Duchenne muscular dystrophy (Q30300638) (← links)
- Therapeutics development in myotonic dystrophy type 1. (Q30425796) (← links)
- Slowing of central conduction in X-linked Charcot-Marie-Tooth neuropathy shown by brain stem auditory evoked responses (Q30495725) (← links)
- Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice (Q30626615) (← links)
- Design and pilot validation of A-gear: a novel wearable dynamic arm support (Q30664937) (← links)
- CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice (Q30725695) (← links)
- Early stages of building a rare disease registry, methods and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR). (Q30832937) (← links)
- Neurobehavioral Concerns Among Males with Dystrophinopathy Using Population-Based Surveillance Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (Q30960550) (← links)
- Caenorhabditis elegans in the study of SMN-interacting proteins: a role for SMI-1, an orthologue of human Gemin2 and the identification of novel components of the SMN complex (Q33257010) (← links)
- Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). (Q33435057) (← links)